公司全资子公司哈药集团三精制药有限公司（以下简称"三精制药"） 原持有哈药集团三精千鹤制药有限公司（以下简称"三精千鹤"）57.18% 的股权，董事会同意三精制药以2,344.60万元受让自然人持有的三精千鹤 将有利于优化资源配置、深化业务协同，进一步增强业务板块的市场竞争 力。公司董事会授权管理层具体办理本次对外投资相关事宜。 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披 露的《哈药集团股份有限公司关于公司全资子公司收购股权的公告》（公 告编号：2025-019）。 证券代码:600664 证券简称:哈药股份 编号:临 2025-018 哈药集团股份有限公司 十届十四次董事会决议公告 本公 司董事 会及全 体董 事保证 公告内 容不存 在任何 虚假记 载、 误导性 陈述或 者重大 遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 哈药集团股份有限公司（以下简称"公司"）第十届董事会第十四次 会议以书面方式发出通知，于 2025 年 5 月 15 日以现场结合通讯形式召开。 会议应参加董事 9 人，实际参加董事 9 人，会议召开符合《中华人民共和 国公司法》和《公司章程》 ...

证券代码:600664 证券简称:哈药股份 编号:临 2025-020 交易简要内容：哈药集团股份有限公司（以下简称"公司"）拟通 过挂牌出租的方式对位于哈尔滨市道外区南直路 326 号的分公司哈药集 团制药六厂（以下简称"哈药六厂"）部分闲置厂房进行资产盘活。 根据《上海证券交易所股票上市规则》《上市公司重大资产重组管 理办法》，上述事项无须提交股东大会审议，也不构成关联交易和重大 资产重组。 相关风险提示：受政策、市场环境变化等因素影响，本次闲置资产 盘活方案在交易对方、交易价格及实施进度等方面仍存在不确定性，敬 请投资者理性决策，注意防范投资风险。 一、交易概述 为盘活存量闲置资产，提高资产使用效率，公司对位于哈尔滨市道 外区南直路 326 号的哈药六厂闲置厂房制定了综合规划方案，根据规划 方案，公司拟通过挂牌出租的方式对部分闲置厂房进行资产盘活。 公司于 2025 年 5 月 15 日召开第十届董事会第十四次会议，审议通 过了《关于公司分公司挂牌出租部分闲置资产的议案》，董事会同意对 分公司哈药六厂南直路部分闲置厂区及房产整体挂牌出租，授权公司管 理层开展后续挂牌以及合同签订等事项。本次授权决议的有效 ...

证券代码:600664 证券简称:哈药股份 编号:临 2025-019 哈药集团股份有限公司 关于公司全资子公司收购股权的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资标的名称：哈药集团股份有限公司（以下简称"公司"）全资 子公司哈药集团三精制药有限公司（以下简称"三精制药"）拟收购三名 自然人所持有的哈药集团三精千鹤制药有限公司（以下简称"标的公司" 或"三精千鹤"）42.82%的股权。收购后，三精千鹤成为三精制药的全资 子公司。 投资金额：本次投资金额为 2,344.60 万元人民币，资金来源于三精 制药自有资金。 相关风险提示： 1、本次拟对外投资事项涉及的相关正式协议尚未签署，后续是否能签 署正式协议、交易能否最终完成尚存在不确定性。 2、本次股权收购实施后，标的公司是否能够高效、顺利运营并达成预 期目标存在一定的不确定性，可能面临行业、政策、市场环境变化及经营 管理等风险,投资收益存在不确定性，敬请投资者注意投资风险。 一、对外投资概述 近日，三精千鹤自然人股东就三精千鹤股权有关事宜提起诉讼 ...

证券代码:600664 证券简称:哈药股份 编号:临 2025-018 二、《关于公司分公司挂牌出租部分闲置资产的议案》（同意9票，反 对0票，弃权0票） 为了盘活公司资产，提高资产使用效率，根据房地产市场环境变化情 况，适时调整公司闲置资产处置策略，董事会同意对公司分公司哈药六厂 南直路部分闲置厂区及房产整体挂牌出租，授权公司管理层开展后续挂牌 哈药集团股份有限公司 十届十四次董事会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 哈药集团股份有限公司（以下简称"公司"）第十届董事会第十四次 会议以书面方式发出通知，于 2025 年 5 月 15 日以现场结合通讯形式召开。 会议应参加董事 9 人，实际参加董事 9 人，会议召开符合《中华人民共和 国公司法》和《公司章程》的有关规定，会议审议了如下议案： 一、《关于公司全资子公司收购股权的议案》（同意 9 票，反对 0 票，弃权 0 票） 公司全资子公司哈药集团三精制药有限公司（以下简称"三精制药"） 原持有哈药集团三精千鹤制药有限公司（以下简称"三精千鹤"）57.18 ...

哈药股份（600664）公告，公司全资子公司哈药集团三精制药有限公司拟收购三名自然人所持有的哈药 集团三精千鹤制药有限公司42.82%的股权，收购金额为2344.6万元人民币。收购完成后，三精千鹤将成 为三精制药的全资子公司。三精千鹤2024年营业收入5502.89万元，净利润39.07万元。 ...

有投资者询问，未来两年公司会有哪些比较有前景的重磅品种。管理层介绍，公司2025年已有乳果糖口服溶液一个仿 制药获批上市，注射用头孢西丁钠（1.0g）、注射用头孢他啶（1.0g、1.5g）两个品种通过仿制药一致性评价。 公司将强力推进在研项目，预计近两年将有磷酸奥司他韦干混悬剂、蛋白琥珀酸铁口服溶液等仿制药获批，以及拉西 地平片、注射用头孢哌酮钠舒巴坦钠等品种将通过仿制药一致性评价。根据公司研发中长期规划，公司将继续聚焦心 脑血管、消化代谢、呼吸系统、抗感染、抗肿瘤等主要疾病领域，大力开展老年人用药、儿童用药和大健康产品的开 发，力争研发出具有质量和成本竞争力、技术差异化优势的产品。 5月14日，哈药股份参与黑龙江辖区上市公司2025年投资者网上集体接待日暨业绩说明会。会上管理层介绍，公司 GNC中国业务近年来收入大幅增加，利润稳步提升，但在费用管理方面仍存在优化空间。未来，公司将积极挖掘商业 合约推广潜力，多举措积极推进降本增效工作，降低销售费用投入，提高费用投放的精准性，不断加强销售费用精细 化管理。同时，紧盯市场动态，强化品牌价值，促进GNC中国业务合规、高质量发展。 此外，管理层也介绍，促红素作为经典 ...

证券代码：600664 证券简称：哈药股份 编号：临 2025-017 哈药集团股份有限公司 会议召开地点："全景路演"网站（http://rs.p5w.net）、"全景财经" 微信公众号、"全景路演"APP 会议召开方式：网络远程方式 投资者可于 2025 年 5 月 7 日(星期三)至 5 月 13 日(星期二)16:00 前访问 https://ir.p5w.net/zj/，或扫描下方二维码进入问题征集专题页面，亦可将有 关问题通过电子邮件形式发送至公司邮箱：master@hayao.com，公司将在信息披 露允许的范围内就投资者普遍关注的问题进行回答。 哈药集团股份有限公司（以下简称"公司"）已于 2025 年 4 月 25 日发布公司 2024 年度报告、2025 年第一季度报告。为了进一步加 强与投资者的互动交流，便于广大投资者更全面深入地了解公司经营 成果、财务状况，公司将参加由黑龙江省上市公司协会与深圳市全景 网络有限公司联合举办的"2025 年黑龙江辖区上市公司投资者集体 接待日活动"暨召开 2024 年度及 2025 年第一季度业绩说明会，在信 息披露允许的范围内就投资者普遍关注的问题进行 ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of RMB 4.95 [8][9][5] Core Views - The company reported revenue, net profit attributable to the parent, and net profit excluding non-recurring items for 2024 at RMB 161.8 million, RMB 6.3 million, and RMB 5.9 million respectively, representing year-on-year growth of 5%, 59%, and 80% [1] - The management team and operational reforms since the end of 2023 are expected to drive sustained profit growth and brand value reassessment [1] - Industrial revenue is projected to grow nearly 20% year-on-year in 2024, with expectations of double-digit growth from 2025 to 2027 [2] - The industrial net profit margin is expected to increase significantly in 2024, with a forecasted margin of 7.7% compared to 3.5% in 2023 [3] - The subsidiary, Renmin Tongtai, is facing revenue pressure with a projected decline of 3% year-on-year in 2024 [4] Summary by Sections Financial Performance - For Q1 2025, the company reported revenue of RMB 41.7 million, net profit attributable to the parent of RMB 2.1 million, and net profit excluding non-recurring items of RMB 2.0 million, reflecting year-on-year growth of 1%, 20%, and 28% respectively [1] - The company expects net profit attributable to the parent for 2025 to reach RMB 7.3 million, with a year-on-year growth of 16.5% [5] Revenue and Profitability - The industrial segment's revenue is expected to grow by 19% to RMB 62.8 million in 2024, with a strong performance in the health supplement category [2] - The industrial net profit margin is estimated to be 11.8% in Q1 2025, significantly up from previous periods due to cost reduction and efficiency improvements [3] Subsidiary Performance - Renmin Tongtai's revenue is projected to be RMB 100 million in 2024, down 3% year-on-year, with profits expected to decline by 27% due to market pressures [4] Valuation Metrics - The report provides a PE valuation of 17x for 2025, aligning with the median expectations of comparable companies [5] - The company’s market capitalization is reported at RMB 9.268 billion, with a closing price of RMB 3.68 as of April 28 [9]

Investment Rating - The investment rating for Harbin Pharmaceutical Group Co., Ltd. is "Buy" [2] Core Views - The report indicates that the company has reached a performance inflection point in 2024, with significant growth driven by operational improvements that are expected to be sustainable [6] - The company achieved a revenue of 16.176 billion yuan in 2024, a year-on-year increase of 4.65%, and a net profit attributable to shareholders of 629 million yuan, up 59.1% year-on-year [3][6] - The report maintains a positive outlook for 2025, projecting continued operational improvements and sustained growth [9] Financial Performance Summary - In 2024, the company reported total revenue of 161.76 billion yuan, with industrial revenue contributing 62.77 billion yuan, a 19.09% increase year-on-year [6] - The company's net profit for 2024 was 6.29 billion yuan, with a non-recurring net profit of 5.86 billion yuan, both exceeding previous forecasts [6][7] - For Q1 2025, the company achieved revenue of 41.74 billion yuan, a 0.78% increase year-on-year, and a net profit of 2.13 billion yuan, up 20.48% year-on-year [3][7] Product and Segment Performance - Key products such as zinc gluconate oral solution and Harbin brand calcium iron zinc oral solution have shown rapid growth [5] - The nutrition supplement segment generated 37.53 billion yuan in revenue, a 30.96% increase year-on-year, while the cardiovascular segment saw a 48.88% increase [6] - The e-commerce segment also performed well, with revenue from Harbin Pharmaceutical Hong Kong reaching 1.458 billion yuan, a 36.4% increase year-on-year [6] Future Projections - The company is expected to achieve revenues of 172.59 billion yuan, 184.88 billion yuan, and 197.9 billion yuan for the years 2025, 2026, and 2027, respectively, with a consistent growth rate of approximately 7% [9] - Projected net profits for the same years are 740 million yuan, 882 million yuan, and 1.045 billion yuan, reflecting year-on-year growth rates of 18%, 19%, and 19% [9]

Investment Rating - The investment rating for Harbin Pharmaceutical Group Co., Ltd. is "Buy" [2] Core Views - The report indicates that the company has reached a performance inflection point in 2024, with significant growth driven by operational improvements that are expected to be sustainable [6] - The company achieved a revenue of 16.176 billion yuan in 2024, a year-on-year increase of 4.65%, and a net profit attributable to shareholders of 629 million yuan, up 59.1% year-on-year [3][6] - The report maintains a positive outlook for 2025, projecting continued operational improvements and maintaining the "Buy" investment rating [9] Summary by Sections Financial Performance - In 2024, the company reported a total revenue of 161.76 billion yuan, with industrial revenue contributing 62.77 billion yuan, a year-on-year increase of 19.09% [6] - The net profit attributable to shareholders for 2024 was 6.29 billion yuan, reflecting a 59.1% increase year-on-year, while the non-recurring net profit was 5.86 billion yuan, up 80.08% [3][6] - For Q1 2025, the company achieved a revenue of 4.174 billion yuan, a 0.78% increase year-on-year, and a net profit of 213 million yuan, up 20.48% year-on-year [3] Business Segments - Key products such as zinc gluconate oral solution and Harbin brand calcium iron zinc oral solution have shown rapid growth [5] - The nutrition supplement business generated 37.53 billion yuan in revenue, a year-on-year increase of 30.96% [6] - The industrial segment's net profit margin improved significantly, reaching approximately 11.85% in Q1 2025, an increase of 4.2 percentage points year-on-year [7] Future Projections - The company is expected to achieve revenues of 172.59 billion yuan, 184.88 billion yuan, and 197.9 billion yuan for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of approximately 7% [9] - The projected net profit attributable to shareholders for the same years is 740 million yuan, 882 million yuan, and 1.045 billion yuan, with respective growth rates of about 18% [9]